Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IUAb190708 in solid tumor. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
IUAb190708
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07584954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584954.